Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2022 06:58 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Resumes Enrollment in BCX9930 Clinical Program

RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has lifted its partial...
July 21, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Report Second Quarter 2022 Financial Results on August 4

RESEARCH TRIANGLE PARK, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2022 financial results...
July 15, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., July 15, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 1st Annual...
July 01, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)

RESEARCH TRIANGLE PARK, N.C., July 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new long-term efficacy and safety data from the APeX-2 and APeX-S...
June 22, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022

RESEARCH TRIANGLE PARK, N.C., June 22, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy...
June 09, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America

RESEARCH TRIANGLE PARK, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into an exclusive collaboration with Pint Pharma...
June 08, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

FDA Grants Fast Track Designation for BioCryst’s ALK-2 Inhibitor, BCX9250

RESEARCH TRIANGLE PARK, N.C., June 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track...
June 07, 2022 09:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic

RESEARCH TRIANGLE PARK, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Swissmedic has granted marketing authorization for oral, once-daily...
June 06, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks

RESEARCH TRIANGLE PARK, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Health Canada has approved oral, once-daily ORLADEYO®...
June 01, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies Healthcare Conference in...